New Model Release: APAP model mice
We are excited to announce the launch of our latest disease model, the Acetaminophen (APAP)-induced Acute Liver Failure (ALF) model.
APAP is one of the most widely used antipyretic and analgesic drugs. However, an overdose of APAP can lead to severe liver damage, resulting in ALF. It has been reported that APAP-related ALF accounts for nearly 50% of all ALF cases in the United States.
In mice, an overdose of APAP also causes severe liver damage as seen in human ALF. Therefore, it is possible to evaluate the efficacy of anti-ALF drugs with a high clinical translatability, comparing with the other ALF mice model.
As shown in the figure below, our APAP model replicates the important pathophysiological features of human ALF.
– Increased ALT level
– Necrotic foci and inflammatory cell infiltration in the liver
We have now begun offering the APAP model as our fifth model in the ALF area.
Besides APAP model, we are proud to offer four different types of ALF models, each specifically designed to meet the needs of our clients and the mode of action of the test compound:
– CCl4-induced acute liver failure model
– Concanavalin A (ConA)-induced autoimmune hepatitis
– Thioacetamide (TAA)-induced drug-induced liver injury model
– Acetaminophen (APAP)-induced drug-induced liver injury model
– LPS/D-GalN-induced acute liver injury model
Do you need such an ALF model?
If you found the above information interesting and would like to learn more about our APAP model, please do not hesitate to contact us. And we would also be happy to arrange a Zoom meeting where you can have the chance to discuss with our marketing and science team about our services and how we might assist your project.
I hope you have a great rest of your day, and I hope to hear from you soon!